Vivimed Labs postpones board meeting for FY26 results

Vivimed Labs Limited has postponed the Board Meeting scheduled for May 30, 2026, which was convened to approve the financial results for the quarter and year ended FY 2025-2026. The company has not yet announced a revised date for the meeting, stating that it will be intimated to the stock exchanges in due course. This delay impacts the timeline for the release of the company's Q4 and FY26 standalone and consolidated financial results.

The board was originally scheduled to meet on May 28, 2026, before being rescheduled to May 30, 2026. The meeting is intended to review and approve the financial statements for both standalone and consolidated operations. The outcome is critical for shareholders as it will determine the company's financial performance for the full fiscal year and the final quarter.

Consequently, the trading window for dealing in the company's securities remains closed for designated persons. This restriction will continue until 48 hours after the declaration of the financial results following the rescheduled meeting.

The regulatory filing was submitted to BSE Limited and National Stock Exchange of India Ltd. to inform the exchanges of the postponement under Regulation 30. The company's BSE code is 532660, and its NSE symbol is VIVIMEDLAB.

Event Details	Information
Original Meeting Date	May 28, 2026
First Rescheduled Date	May 30, 2026
Current Status	Postponed (Revised date awaited)
Agenda	Financial Results (Standalone & Consolidated) for Q4 and FY ended March 31, 2026
Trading Window Status	Closed until 48 hours post-results declaration

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.32%	-3.86%	-9.26%	-77.52%	-77.52%	-4.32%

Vivimed Labs has informed the stock exchanges of an upcoming Board of Directors meeting scheduled for Thursday, May 28, 2026, to be held at Hyderabad. The intimation, dated May 16, 2026, was filed pursuant to Regulation 29 of the SEBI (Listing Obligations & Disclosure Requirements), 2015.

Board Meeting Agenda

The primary purpose of the meeting is to consider and approve the audited financial results of the company for the quarter and year ending March 31, 2026. The Board will review both standalone and consolidated financial statements, in addition to any other items that may be placed before it.

Key details of the scheduled meeting are summarised below:

Parameter:	Details
Meeting Date:	Thursday, May 28, 2026
Meeting Location:	Hyderabad
Notice Date:	May 16, 2026
Regulatory Compliance:	Regulation 29, SEBI (LODR), 2015
Financial Period Under Review:	Quarter and year ending March 31, 2026
Results Type:	Audited Standalone & Consolidated

Regulatory Compliance

The notice was issued in accordance with Regulation 29 of the SEBI (Listing Obligations & Disclosure Requirements), 2015, which mandates listed companies to provide advance intimation to stock exchanges prior to board meetings where financial results are to be considered. The communication was signed by Yugandhar Kopparthi, Company Secretary of Vivimed Labs.